Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of INE963 in Healthy Participants
NCT04896632Phase 1Terminated
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INE963 in malaria (4 arms), sponsored by Novartis. Primary endpoint: Number of Subjects with Significant Clinical Safety Labs, reporting SAEs and AEs and ECG findings at 21 days. Started May 2021; status: terminated.
02
Drugs
INE963
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04896632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896632.